PENELOPE-B: Palbociclib Disappoints in HR+, HER2 – Breast Cancer PENELOPE-B: Palbociclib Disappoints in HR+, HER2 – Breast Cancer

The CDK4/6 inhibitor palbociclib provides no significant benefit in patients with HR+, HER2-negative primary breast cancer, according to first results from the PENELOPE-B trial.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news